TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 799563
Drug: Hydrochlorothiazide +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide + amiloride (25 mg + 2-5 mg)
Study: 799563
Drug: Timolol +
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol + hydrochlorothiazide + amiloride (10 mg + 25 mg + 2-5 mg)
Study: 21054800
Drug: Topical misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical misoprostol (100 µg)
Study: 17853018
Drug: Bilateral periprostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral periprostatic infiltration of 5 cm(3) of 0.9% saline solution
Study: 2896828
Drug: Edmonston-Zagreb (E-Z)
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb (E-Z) measles vaccine, 40,000 plaque forming units
Study: 2896828
Drug: Schwarz vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz vaccine, 40,000 plaque forming units
Study: 28402415
Drug: Single-dose misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose misoprostol (800 μg vaginally on Day 1)
Study: 28402415
Drug: Repeat-dose misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeat-dose misoprostol (800 μg vaginally on Day 1, with a second dose if required on Day 4)
Study: 28402415
Drug: Repeat-dose misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeat-dose misoprostol
Study: 26185033
Drug: BMP-2/H (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMP-2/H (1 mg/mL of rhBMP-2 soaked with hydroxyapatite granules, 0.5 to 2.0 g; n = 65)
Study: 26185033
Drug: ABX (inorganic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX (inorganic bovine bone xenograft, 0.5 to 2.0 g; n = 62)
Study: 23295964
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and hepatitis B vaccine (first dose)
Study: 23295964
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and hepatitis B vaccine (third dose)
Study: 23295964
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and hepatitis B vaccine (first booster dose)
Study: 14658976
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable risperidone (25 mg, 50 mg, or 75 mg every 2 weeks for 12 months)
Study: 9179067
Drug: Nonabsorbable antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonabsorbable antibiotic lozenge
Study: 3530781
Drug: Bucindolol 50
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol 50 mg
Study: 2866786
Drug: Bucindolol 200
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol 200 mg
Study: 19557424
Drug: Cocktail therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail therapy (ESWT, HBO, alendronate)
Study: 19557424
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave treatment (ESWT) alone
Study: 16042638
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement and behavioral therapies
Study: 10518846
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 0.25 mg once daily
Study: 24229823
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 0.5 mg once daily
Study: 10518846
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 1.0 mg once daily
Study: 10518846
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 0.25 mg twice daily
Study: 10518846
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 0.5 mg twice daily
Study: 10518846
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 1.0 mg twice daily
Study: 10518846
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 0.25 mg once daily (study C)
Study: 10518846
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 0.5 mg twice daily (study C)
Study: 10518846
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 1.0 mg once daily (study C)
Study: 8748720
Drug: Topical terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical terbutaline sulfate (1.0 mg)
Study: 7004292
Drug: Bethanechol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol (25 mg tablets, four times daily for 4 weeks)
Study: 7004292
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four times daily for 4 weeks)
Study: 31514744
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (fixation) of medial malleolus fractures
Study: 31514744
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (non-fixation) of medial malleolus fractures
Study: 31514744
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (fixation)
Study: 31514744
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (non-fixation)
Study: 28990241
Drug: Clinically indicated
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically indicated replacement of peripheral intravenous catheters (PIVC)
Study: 28990241
Drug: Routine replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine replacement of peripheral intravenous catheters (PIVC) every 72-96 hours
Study: 25381876
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + low-dose metformin
Study: 19741313
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (25 g/day for 7 days, then 5 g/day for 14 days)
Study: 19741313
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 g/day glucose for 7 days, then 30 g/day glucose for 14 days)
Study: 17559754
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER (100 mg, 200 mg, 300 mg, or 400 mg once daily)
Study: 31221619
Drug: Epacadostat 100
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg intravenously every 3 weeks
Study: 24130088
Drug: Autologous skeletal
Normalized name: Spongia officinalis skeleton extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous skeletal myoblast transplantation (ASM-Tx) - low dosage (400 million cells)
Study: 24130088
Drug: Autologous skeletal
Normalized name: Spongia officinalis skeleton extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous skeletal myoblast transplantation (ASM-Tx) - high dosage (800 million cells)
Study: 22241513
Drug: Esomeprazole (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (2.5-10 mg) once daily for 2 weeks, followed by weight-adjusted doses for 4 weeks.
Study: 22241513
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 4 weeks after initial treatment.
Study: 22241513
Drug: Esomeprazole (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (2.5-10 mg) for infants with symptomatic GERD.
Study: 20090377
Drug: Individualized parenteral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized parenteral nutrition (IPN)
Study: 20090377
Drug: Standardized parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized parenteral nutrition (SPN)
Study: 12731753
Drug: Zanamivir intranasal
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir intranasal spray (6.4 mg)
Study: 1656040
Drug: Metoprolol (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100-200 mg once daily)
Study: 31577749
Drug: Low-dose misoprostol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose misoprostol combined with mifepristone
Study: 27411564
Drug: UNIMMAP containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: UNIMMAP containing 60 mg/d iron (reference arm)
Study: 27411564
Drug: UNIMMAP containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: UNIMMAP containing 60 mg/d iron based on weekly hepcidin screening
Study: 27411564
Drug: UNIMMAP containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: UNIMMAP containing 30 mg/d iron for 12 weeks
Study: 22283356
Drug: Mobile phone
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile phone diaries for daily symptom reporting via morning and evening questionnaires.
Study: 12885800
Drug: Intraperitoneal chromic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal chromic phosphate suspension (32P) therapy (15 mCi)
Study: 12885800
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (NFT)
Study: 10776506
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of antiovarian antibody in POF patients
Study: 8933855
Drug: Atropine premedication
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine premedication (0.01 mg/kg intramuscularly 30 min before procedure)
Study: 1896817
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole (140 mg/day)
Study: 1896817
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole (200 mg/day)
Study: 1896817
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole (both doses)
Study: 26104223
Drug: Group problem-solving
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group problem-solving therapy
Study: 7649340
Drug: Astemizole-D (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole-D (10 mg astemizole/240 mg pseudoephedrine)
Study: 7649340
Drug: Loratadine-D (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine-D (5 mg loratadine/120 mg pseudoephedrine)
Study: 1067352
Drug: Combined preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preventive measures including ingestion of fluoridated water (1.0 ppm), topical application of acidulated phosphate fluoride, application of a pit and fissure sealant, early detection of caries, restoration of affected teeth, and dental health education.
Study: 31964219
Drug: Doxorubicin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin + Black Seed Oil (80 mg/kg/dose, divided into 3 doses for 1 week after each doxorubicin dose)
Study: 19317823
Drug: Insulin dose
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dose calculated for 60 g CHO
Study: 19317823
Drug: 70-g meal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70-g meal
Study: 8020524
Drug: Iomeprol 300
Normalized name: Iomeprol 300 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 300 mgI/ml at 3 ml/s
Study: 8020524
Drug: Iomeprol 200
Normalized name: IOMEPROL
DrugBank: Iomeprol (DB11705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 200 mgI/ml at 3 ml/s
Study: 8020524
Drug: Iomeprol 300
Normalized name: Iomeprol 300 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 300 mgI/ml at 2 ml/s
Study: 8020524
Drug: Iomeprol 200
Normalized name: IOMEPROL
DrugBank: Iomeprol (DB11705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 200 mgI/ml at 2 ml/s
Study: 16822112
Drug: GA referral
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA referral plus 8 sessions of individual CB therapy
Study: 12839616
Drug: Imiquimod cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod cream, applied topically three times a week
Study: 1698137
Drug: Diethylaminoethyl-dextran (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylaminoethyl-dextran (3 g total) taken 30 min before a standard mixed test meal
Study: 6163165
Drug: Pentoxifylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (300 mg to 600 mg orally for 3 months)
Study: 6163165
Drug: Conventional fibrinolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fibrinolytic agents only (Control)
Study: 27923158
Drug: 40mg/day atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/day atorvastatin
Study: 27923158
Drug: Combined 10mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 10mg/day atorvastatin with 10mg/day ezetimibe
Study: 24449008
Drug: Group G
Normalized name: Prostaglandin group G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G (gradual perturbation)
Study: 17391225
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propofol (25 microg/kg per minute) and ketamine (25 microg/kg per minute)
Study: 17391225
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propofol (25 microg/kg per minute) and ketamine (12.5 microg/kg per minute)
Study: 12036167
Drug: Oxycodone 10
Normalized name: oxycodone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 10 mg/Acetaminophen 1,000 mg
Study: 10440879
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy after transurethral resection
Study: 3135609
Drug: 1.4 g
Normalized name: MENTHOL 1.4 g in 100 g TOPICAL CREAM [Cetilar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g of pivampicillin plus 1.0 g of probenecid, taken once a day for five days
Study: 3135609
Drug: Sulfamethoxazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfamethoxazole (400 mg) and trimethoprim (80 mg), single ten-tablet dose on the first day, two five-tablet doses on the second day, and two three-tablet doses for the next three to five days
Study: 3135609
Drug: Sulfamethoxazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfamethoxazole (400 mg) and trimethoprim (80 mg), single ten-tablet dose on the first day and two five-tablet doses on the second day
Study: 26423742
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNSs) 500 kcal/d
Study: 21942363
Drug: Immediate dental
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate dental implants without any filling material around the implants (Group A)
Study: 21942363
Drug: Pure-phase multiporous
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure-phase multiporous beta-tricalcium phosphate (beta-TCP) packed into the bone gaps around the implants (Group B)
Study: 18445665
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy (66 microg/kg.d) for 2 years in group 3 (78 patients from group 1)
Study: 18445665
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group 1 and group 2 without GH therapy)
Study: 20069533
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy (CST), a 14-session group treatment
Study: 16101937
Drug: Live Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live Lactobacillus paracasei (LP33) - 5 x 10(9) colony-forming units/capsule, 2 capsules per day for 30 days
Study: 16101937
Drug: Heat-killed Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed Lactobacillus paracasei (LP33) - 5 x 10(9) colony-forming units/capsule, 2 capsules per day for 30 days
Study: 16101937
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 2 capsules per day for 30 days
Study: 12468781
Drug: Oral citicoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral citicoline (500, 1000, and 2000 mg)
Study: 12468781
Drug: Oral citicoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral citicoline (2000 mg)
Study: 8067216
Drug: Interpleural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpleural analgesia with bupivacaine 5 mg.ml‐1 and 5 microgram epinephrine, 30 ml bolus, continuous infusion at 7 ml/hour
Study: 8067216
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with bupivacaine 3.75 mg.ml‐1 and 5 microgram epinephrine, 5 ml bolus, continuous infusion at 5 ml/hour
Study: 3289648
Drug: Alprazolam 4
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam 4 mg/day
Study: 3289648
Drug: Chlormethiazole 3.072
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormethiazole 3.072 g/day (equivalent to 8 g of the edisylate)
Study: 30683060
Drug: Pharmacist's medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist's medication review combined with a communication pathway to GPs and nursing home staff, facilitation of change in interprofessional cooperation, educational training, and a toolbox for implementation.
Study: 30683060
Drug: Pharmacist's medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist's medication review and interprofessional cooperation measures.
Study: 29317015
Drug: BDP BAI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP BAI 320 μg/day
Study: 29317015
Drug: BDP BAI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP BAI 640 μg/day
Study: 29317015
Drug: BDP MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP MDI 320 μg/day
Study: 25037985
Drug: Control of
Normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control of physiotherapist twice monthly (1 day/2 weeks) - Group 2
Study: 20303323
Drug: 75 IU
Normalized name: Follitropin Beta 75 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 IU recombinant follicle-stimulating hormone (rFSH)/day
Study: 17354182
Drug: Adjuvant hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant hypertonic glucose solution injections
Study: 15371046
Drug: Paraffin bath
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin bath treatment combined with hand exercise
Study: 11591551
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (two 200-microg puffs bid; budesonide group, n = 19)
Study: 11591551
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (symptomatic group, n = 19)
Study: 9845852
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg day‐1 and step 1 diet
Study: 9845852
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg day‐1 and step 2 diet
Study: 3058228
Drug: High-dose nandrolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nandrolone decanoate for 3 months in Group II (44 patients with moderate or chronic severe aplastic anemia)
Study: 21048773
Drug: Walnut supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut supplementation (15 g/day for 4 weeks)
Study: 12867226
Drug: Fexofenadine 180
Normalized name: fexofenadine 180 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 180 mg alone
Study: 12867226
Drug: Fexofenadine 180
Normalized name: fexofenadine 180 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 180 mg with alcohol (0.3 g/kg body weight)
Study: 12867226
Drug: Hydroxyzine 50
Normalized name: hydroxyzine hydrochloride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 50 mg with alcohol
Study: 10559084
Drug: Omeprazole, 40
Normalized name: Omeprazole, 40 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 40 mg qd for 8 weeks
Study: 6605682
Drug: Fenbufen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenbufen (600 or 900 mg daily)